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Summary
The conservation of structure across paralog proteins
promotes alternative protein-ligand associations often
leading to side effects in drug-based inhibition. How-
ever, sticky packing defects are typically not con-
served across paralogs, making them suitable targets
to reduce drug toxicity. This observation enables
a strategy for the design of highly specific inhibitors in-
volving ligands that wrap nonconserved packing de-
fects. The selectivity of these inhibitors is evidenced
in affinity assays on a cancer-related pharmacoki-
nome: a powerful inhibitor is redesigned by using the
wrapping technology to enhance its selectivity and af-
finity for a target kinase. In this way, the packing de-
fects of a soluble protein may be used as selectivity fil-
ters for drug design.
Introduction
The function of soluble proteins requires stable folds
that often rely on associations to maintain their integrity
(Dunker et al., 2002; Huber, 1979; Verkhivker et al., 2003).
Isolated structures with packing defects arising as
poorly protected hydrogen bonds do not typically pre-
vail in water (Ferna´ndez, 2004; Ferna´ndez and Berry,
2004). Here, we show that packing defects may be tar-
geted to develop a novel, to our knowledge, type of
highly selective inhibitor. Furthermore, the inspection
of protein-inhibitor complexes of reported structure
(Fauman et al., 2003; Stevens, 2004; Wlodawer and Von-
drasek, 1998; Arkin and Wells, 2004; Katz et al., 2000;
Steinmetzer et al., 2001) supports the design concept
of an inhibitor as a wrapper of packing defects and of
a packing defect as a selectivity filter.
While structural conservation holds across paralogs,
packing defects are often not conserved (Ferna´ndez
and Berry, 2004). Thus, side effects resulting from off-
target ligand binding may be minimized by selectively
targeting nonconserved packing defects with the guid-
ance of a measure of packing similarity, as shown in
this work.
Structural descriptors of protein binding sites, such as
hydrophobicity (Nicholls et al., 1991), curvature (Liang
et al., 1998), and accessibility (Lee and Richards, 1971)
are routinely used to guide inhibitor design. However,
upon examination of the 814 nonredundant protein-
inhibitor PDB complexes, it is apparent that in 488 of
*Correspondence: arifer@rice.eduthem, the binding cavity has an average hydrophobicity
not significantly higher than the rest of the surface. In
such cases, ligand affinity is attributed to the intermo-
lecular hydrogen-bonding propensities of the inhibitor,
inferred from protein-substrate transition-state mimetics
(Wlodawer and Vondrasek, 1998; Arkin and Wells, 2004;
Katz et al., 2000; Steinmetzer et al., 2001). However,
charge screening in water renders putative intermolecu-
lar hydrogen bonds unlikely promoters of protein-ligand
association, unless other factors are present at the inter-
face to foster water removal (Ferna´ndez and Scheraga,
2003).
One such factor has been recently identified. We have
reported (Ferna´ndez, 2004; Ferna´ndez and Berry, 2004,
Ferna´ndez and Scheraga, 2003) that packing defects in
proteins, the so-called dehydrons (Ferna´ndez and
Berry, 2004; Deremble and Lavery, 2005), or underwrap-
ped hydrogen bonds, constitute sticky sites with a
propensity to become dehydrated. The term ‘‘wrapping’’
indicates a clustering of nonpolar groups framing an an-
hydrous microenvironment. Dehydrons are signaled by
insufficient intramolecular wrappers and promote pro-
tein-ligand associations that ‘‘correct’’ packing defects
(Ferna´ndez and Scheraga, 2003; Deremble and Lavery,
2005). Their stickiness arises from the charge-screening
reduction resulting from bringing nonpolar groups into
proximity: water exclusion enhances and stabilizes pre-
formed electrostatic interactions. A few (<7) nonpolar
groups wrapping a hydrogen bond simply prevent the
hydration of the amide and carbonyl, but a sufficient
number of wrappers, while making hydration thermody-
namically costly, introduce a compensation by enhanc-
ing the stability of the hydrogen bond (Ferna´ndez and
Scott, 2003).
We start by showing that in most PDB protein-
inhibitor complexes, the ligand is in effect a wrapper of
packing defects in the protein, although it was not pur-
posely designed to fulfill this role. In this way, the design
concept of ligand as a dehydron wrapper is supported
by reexamination of structural data. These preliminary
data pave the way to introduce a wrapping technology
in drug design. A proof of principle is provided by dem-
onstrating experimentally that targeting dehydrons that
are not conserved across paralogs becomes a useful
strategy to enhance binding selectivity. Thus, we take
advantage of packing differences to selectively modify
a powerful multiple-target inhibitor to achieve a higher
specificity toward a particular target.
Results
Ligands as Dehydron Wrappers
in Protein-Inhibitor Complexes
The interfaces of the 814 protein-inhibitor PDB com-
plexes were reexamined to determine whether inhibitors
were ‘‘dehydron wrappers,’’ that is, whether nonpolar
groups of inhibitors penetrated the desolvation domain
of dehydrons. This feature was found in 631 complexes,
and it was invariably found in the 488 complexes in
which the binding cavity presented average or no
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1830Figure 1. Structure of HIV-1 Protease with an Inhibitor Acting as a Dehydron Wrapper
A dehydron is identified by determining the extent of the intramolecular desolvation, r, of the hydrogen bond, quantified as the number of non-
polar groups within its desolvation domain. The desolvation domain consists of two intersecting balls of radii 6.4 A˚ centered at the a-carbons of
the paired residues. Most (w92% of the PDB entries) stable folds have at least two-thirds of backbone hydrogen bonds with r = 26.66 7.5. De-
hydrons are hydrogen bonds with r% 19 (their r value is below the mean minus one Gaussian dispersion). The figure shows the Indinavir (Crix-
ivan) inhibitor crystallized in complex with HIV-1 protease (PDB: 2BPX). The packing defects of the dimeric protease are shown in their spatial
relation to the inhibitor position. The protein chain backbone is represented by blue virtual bonds joining a-carbons, well-wrapped backbone
hydrogen bonds are shown as light-gray segments joining the a-carbons of the paired residues, and dehydrons are shown as green segments.
The figure shows in detail the protease cavity, the pattern of packing defects, and the inhibitor positioned as a dehydron wrapper.surface hydrophobicity. This situation is illustrated in
Figures 1 and 2 for the HIV-1 protease (Wlodawer and
Vondrasek, 1998; Munshi et al., 1998) and the uroki-
nase-type plasminogen activator (Katz et al., 2000), re-
spectively. The inhibitor contribution to improve the pro-
tein packing is not fortuitous since the substrate must be
anchored and water must be expelled from the enzy-
matic site. Strikingly, the wrapping of dehydrons is not
purposely attempted in current drug design.
The Merck inhibitor Indinavir (Crixivan) bound to the
functionally dimeric HIV-1 protease (PDB: 2BPX) is
shown in Figure 1 (Wlodawer and Vondrasek, 1998;
Munshi et al., 1998). The dehydrons in the protease are
marked in green. On each monomer, these dehydrons
are backbone hydrogen bonds involving the following
residue pairs: Ala28-Arg87, Asp29-Asn88, Gly49-Gly52,
and Gly16-Gln18. The cavity associated with substrate
binding contains the first three dehydrons, with dehy-
drons 49–52 located in the flap and dehydrons 28–87
and 29–88 positioned next to the catalytic site (Asp25),
to anchor the substrate. This ‘‘sticky track’’ determined
by dehydrons 28–87 and 29–88 is required to align the
substrate peptide across the cavity, as needed for nu-
cleophilic attack by the Asp25s. The flap, on the other
hand, must have an exposed and hence labile hydrogenbond needed to confer the flexibility associated with the
gating mechanism. The lack of protection on the flap
(49–52) hydrogen bond becomes the reason for its
stickiness, as the bond can be strengthened by the ex-
ogenous removal of surrounding water. The positioning
of all three dehydrons in the cavity (six in the dimer) pro-
motes inhibitor association.
Indinavir is a wrapper of packing defects in the enzy-
matic cavity: it contributes 12 desolvating groups to
the 49–52 hydrogen bond, 10 to the 28–87 hydrogen
bond, and 8 to the 29–88 hydrogen bond. All functionally
relevant residues are either polar or expose the polarity
of the peptide backbone (Asp25, Thr26, Gly27, Ala28,
Asp29, Arg87, Asn88, Gly49, Gly52), and, thus, they are
not themselves promoters of protein-ligand association.
The strategic position of dehydrons involving these res-
idues in their microenvironments becomes a decisive
factor in promoting water removal or charge descreening
required in facilitating the enzymatic nucleophilic attack.
Figure 2 shows an inhibitor acting as a wrapper of
packing defects in its complexation with the uroki-
nase-type plasminogen activator (PDB: 1C5W), a prote-
ase associated with tumor metastasis and invasion
(Katz et al., 2000). Figures 2A and 2B reveal dehydrons
Cys191-Asp194, Asp194-Gly197, and Gln192-Lys143 in
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1832Figure 3. The Nonconserved Wrapping across Paralogs Sharing Common Folds with Drug-Targeted Proteins
Dehydron pattern in a-thrombin (PDB: 1A3E), a paralog of the plasminogen activator (PDB: 1C5W) sharing a common domain structure, but
different wrapping, together with the location of the inhibitor within the complex. The figure reveals the role of the inhibitor as a wrapper of
the packing defects in the cavity. Notice the difference in the dehydron pattern of the cavity, distinguishing the a-thrombin from its paralog shown
in Figure 2.the protein cavity. Strikingly, none of the hydrophobic
residues in the cavity contributes to the inhibitor binding
(Figure 2C).
Nonconserved Packing Defects as Highly
Specific Targets
Central to drug design is the minimization of toxic side
effects. Because paralog proteins are likely to share
common domain structures (Mount, 2001), the possibil-
ity of multiple binding partners for a given protein inhib-
itor arises, unless nonconserved features are specifi-
cally targeted. This problem may be circumvented by
targeting dehydrons, because, in contrast to the fold,
the wrapping is generally not conserved (Ferna´ndez
and Berry, 2004).
To determine whether dehydron targeting is likely to
reduce side effects, we first investigated the extent of
the conservation of dehydrons across human paralogs
in the PDB. The paralogs for every crystallized protein-
inhibitor complex were identified, and dehydron pat-terns at binding cavities were compared. A 30% minimal
sequence alignment was required for paralog identifica-
tion. Packing defects were found to be a differentiating
marker in paralogs of 527 out of the investigated 631
proteins crystallized in complex with inhibitors. A pro-
tein chain is often reported in complexes with different
inhibitors.
The PDB contains 440 redundancy-free pairs of hu-
man paralogs. Of these, 308 involve some of the 527 pro-
teins containing binding dehydrons. In 269 pairs, the in-
tramolecular wrapping at the binding cavity differs in the
location or presence of at least 1 dehydron, and, in 203
pairs, the difference extends to 2 or more dehydrons.
Thus, the probability of avoiding cross reactivity by se-
lectively wrapping packing defects is estimated at
88% (269 pairs out of 308).
For instance, a-thrombin (PDB: 1A3E) (Zdanov et al.,
1993), a paralog of the plasminogen activator (PDB:
1C5W), shares a common domain structure, but a differ-
ent dehydron pattern (Figure 3). While the inhibitor of theFigure 2. Inhibitor as a Wrapper of Packing Defects in the Urokinase-Type Plasminogen Activator
(A) Detail of the dehydron pattern of the protein cavity.
(B) The inhibitor-protein complexation revealing the position of the inhibitor as a wrapper of the packing defects in the cavity. The only dehydrons
in a concave region of the protein surface are: Cys191-Asp194, Asp194-Gly197, and Gln192-Lys143. Upon complexation, the inhibitor wraps all
three dehydrons, contributing six nonpolar groups to their desolvation domains.
(C) Hydrophobic residues in the cavity region and their mismatch against polar moieties in the inhibitor across the protein-ligand interface. There
are three nonpolar residues in the rim of the protein cavity, Ile138, Val213, and Trp215, but none is engaged in hydrophobic interactions with the
inhibitor.
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1833Figure 4. Modifications of Gleevec Geared at Improving Selectivity and Affinity for Brc-Abl
(A) Three possible sites for Gleevec methylation (I–III) aimed at selectively improving the wrapping of packing defects of Brc-Abl (PDB: 1FPU).
(B) Structural alignment of Brc-Abl and its six paralogs by using the program Cn3D. The yellow region corresponds to a b hairpin in Brc-Abl cov-
ering amino acids 247–257.
(C) The modified Gleevec-based molecule methylated at sites I and II and assayed in vitro in this study.
(D) Rate of phosphorylation of Brc-Abl (blue), C-kit (green), Lck (red), Chk1 (purple), and Pdk1 (brown) in the presence of Gleevec (triangles) and in
the presence of the I-, II-methylated modified Gleevec (squares). The latter compound was designed to better wrap the nonconserved dehydrons
in Brc-Abl. Within the means of detection, the kinase phosphorylation rates do not vary appreciably in the range of 0–100 nM inhibitor concen-
tration. Error bars represent the dispersion in measurements over ten repetitions of each kinetic assay.a-thrombin is a wrapper of cavity dehydrons (Figure 3),
additional specificity would have been gained if the
inhibitor had been tailored to target the unique dehy-
dron pattern of the cavity (compare Figures 2A and 3).
Specifically, the Ser195-Gly197 dehydron present in
a-thrombin becomes intramolecularly well-wrapped in
the plasminogen activator (Figures 2A and 3).
Proof of Principle: Using Wrapping Technology
to Enhance Drug Specificity
We now provide a proof of principle of the enhanced
selectivity achieved by using wrapping technology. Be-
cause of the evolutionary proximity of kinases (Manning
et al., 2002), side effects arising from off-target ligand
binding often arise with kinase inhibitors, especially in
cancer therapy (Fabian et al., 2005). Nearly all kinase in-
hibitors target the adenosine triphosphate (ATP) binding
pocket, a highly conserved structural feature across the
human kinome (Cohen et al., 2005). Thus, a need arises
to sharpen the binding affinity within the pharmacoki-
nome associated with a specific drug. For instance,the selective inhibition of the Brc-Abl (Abelson tyrosine
kinase), the fusion product of a chromosomal transloca-
tion, is crucial to treat chronic myeloid leukemia (CML)
(Schindler et al., 2000). Brc-Abl has been proven to
be a target for the potent inhibitor Gleevec (Schindler
et al., 2000), but not its only target (Fabian et al., 2005).
Of the alternative targets with reported structure, the
C-kit tyrosine kinase has been recognized as a binding
partner, making Gleevec a therapeutic agent for colo-
rectal cancer (Attoub et al., 2002; Skene et al., 2004). In
addition, Gleevec binds tightly to the lymphocyte kinase
(Lck) (Perlmutter et al., 1988). Thus, we sought to modify
Gleevec to improve its selectivity for Brc-Abl by target-
ing dehydrons not conserved across paralogs.
The protein-inhibitor complex (PDB: 1FPU) (Figure 4A),
reveals three electrostatic interactions in Brc-Abl, the
dehydrons Gly249-Gln252 and Gln300-Glu316 and the
salt bridge Lys271-Glu286, that can be better wrapped
by methylating Gleevec at the positions indicated. Thus,
methylation at positions I, II, and III would contribute
to improve the wrapping of dehydrons 249–252 and
Structure
1834Figure 4. continued300–316 and the salt bridge 271–286, respectively. A
structural alignment of the paralogs of Brc-Abl was per-
formed by using the program Cn3D (http://www.ncbi.
nlm.nih.gov/structure/CN3D/cn3d.shtml) to investigate
the microenvironment conservation for these intra-
molecular interactions. The six kinases reported in the
PDB that aligned with Brc-Abl are: C-kit (PDB: 1T45),
Lck (PDB: 3LCK), Pdk1 kinase (PDB: 1UVR), Cdc42-
associated Tyr kinase Ack1 (PDB: 1U54), epidermal
growth factor receptor (EGFR) kinase (PDB: 1M17), and
the checkpoint kinase Chk1 (PDB: 1IA8). The alignment
is shown in Figure 4B. Dehydron 249–252 (crankshaft-
like kink marked in yellow on Figure 4B) is not conserved
in any of the six paralogs of Brc-Abl, while dehydron 300–
316 becomes well-wrapped in the paralogs. On the other
hand, the microenvironment of the salt bridge 271–286 is
conserved.
In order to enhance affinity and selectivity for Brc-Abl,
we modified the inhibitor methylating at positions I and II(Figure 4C) (Li et al., 2004). To test whether the specific-
ity and affinity for Brc-Abl improved, we conducted
a spectrophotometric assay to measure the phosphory-
lation rate of peptide substrates (Schindler et al., 2000;
Timokhina et al., 1998; Perlmutter et al., 1988; Zhao
et al., 2002; Le Good et al., 1998) in the presence of
the kinase inhibitor at different concentrations. As indi-
cated in Figure 4D, the inhibition of the unphosphory-
lated Brc-Abl by the wrapper of the 249–252 and 300–
316 dehydrons (the I, II methylation product) improved
over Gleevec levels. Furthermore, the inhibitory impact
of the dehydron wrapper became selective for Brc-Abl
vis-a`-vis C-kit and Lck. Dehydrons 249–252 and 300–
316 are absent in the latter kinases, and, consistently,
the drug designed to better wrap them has a very low in-
hibitory impact against C-kit and Lck. Finally, neither
Gleevec nor its modified version showed detectable in-
hibitory impact on the remaining paralogs, Chk1 and
Pdk1, for which substrate peptides have been reported.
Packing as a Drug Selectivity Filter
1835Figure 4. continuedThe results expounded on in Figure 4 substantiate our
claim that nonconserved packing defects may be used
as selectivity filters in drug design.
Discussion
To our knowledge, this study substantiates a novel con-
cept in inhibitor design: packing defects may be tar-
geted by ligands designed to wrap them or shield them
from water attack. Since structure packing is typically
not conserved across paralog proteins, the inhibitory
impact resulting from applying the wrapping technology
is likely to be highly selective, turning packing defects
into selectivity filters. Conversely, the measure of pack-
ing similarity used to lead the inhibitor design may also
be used to implement a multidimensional multiple-
target approach to drug therapy. Future research is ex-
pected to explore this possibility.
The wrapping technology introduced in this work has
biological implications since it hinges on a novel, to our
knowledge, molecular descriptor of the structure/
function multivalued relation. Thus, as noted previously
(Ferna´ndez and Berry, 2004), the packing constitutes
a molecular dimension explored in evolution to foster
new functionalities within an invariant fold. This work re-
veals how this evolutionary footprint may be targeted by
the drug designer in order to enhance selectivity.
Experimental Procedures
Structure-Based Dehydron Identification
Packing defects in the form of dehydrons or underwrapped back-
bone hydrogen bonds may be identified from the atomic coordi-nates of a protein structure in a single or multidomain chain or in
a protein complex in a PDB entry, according to simple tenets (Fer-
na´ndez and Berry, 2004): (1) The extent of intramolecular hydrogen
bond desolvation, r, in the monomeric structure may be quantified
by determining the number of nonpolar groups (carbonaceous, not
covalently bonded to an electrophilic atom) contained within a des-
olvation domain. (2) The desolvation domain is defined as two inter-
secting balls of fixed radii centered at the a-carbons of the residues
paired by the backbone amide-carbonyl hydrogen bond (Ferna´ndez
and Berry, 2004). (3) The extent of desolvation of an intramolecular
hydrogen bond within a protein-ligand or protein-protein complex
requires that the count include nonpolar groups from the monomer
as well as those from its binding partner(s). The statistics of hydro-
gen bond wrapping vary according to the desolvation radius adop-
ted, but the tails of the distribution invariably single out the same
dehydrons in a given structure over a 6.2–7 A˚ range in the adopted
desolvation radius. In this work, the value of 6.4 A˚ was adopted.
In most (w92% of the PDB entries) stable protein folds, at least
two-thirds of the backbone hydrogen bonds are wrapped on aver-
age by r = 26.6 6 7.5 nonpolar groups (or 14.0 6 3.7 counting only
side chain groups and excluding those from the hydrogen bonded
residue pair) (Ferna´ndez and Scheraga, 2003). Dehydrons are here
defined as hydrogen bonds whose extent of wrapping lies in the tails
of the distribution, i.e., with 19 or fewer nonpolar groups in their des-
olvation domains (their r value is below the mean minus one Gauss-
ian dispersion). Dehydrons are dominant factors driving association
in 38% of the PDB complexes (the number of dehydrons per 1000 A˚2
at protein-protein interfaces is more than 3/2 the average density on
individual monomers). Furthermore, dehydrons constitute signifi-
cant factors (interface dehydron density larger than average) in
92.9% of all PDB complexes (Ferna´ndez and Scheraga, 2003; Der-
emble and Lavery, 2005).
Given the inherent stickiness of packing defects in soluble pro-
teins (Ferna´ndez, 2004; Ferna´ndez and Scott, 2003), and the fact
that interfacial water removal from a concave or flat region of the
protein surface entails far less thermodynamic work than removal
from a convex water-clathrated region (Liang et al., 1998), we may
Structure
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design. These structural features become of paramount importance
when the hydrophobicity of the cavity (Nicholls et al., 1991) is not sig-
nificantly higher than the average for a soluble protein surface (Fer-
na´ndez and Scheraga, 2003).
Spectrophotometric Kinetic Assay
To determine the level of selectivity of drug inhibitors designed by
adopting the wrapping technology, kinetic assays of the inhibition
of multiple kinases have been conducted. To measure the rate of
phosphorylation due to kinase activity in the presence of inhibitors,
a standard spectrophotometric assay has been adopted (Schindler
et al., 2000) in which the adenosine diphosphate production is cou-
pled to the NADH oxidation and determined by absorbance reduc-
tion at 340 nm. Reactions were carried out at 35ºC in 500 ml buffer
(100 mM Tris-HCl, 10 mM MgCl2, 0.75 mM ATP, 1 mM phosphoenol
pyruvate, 0.33 mM NADH, 95 U/ml pyruvate kinase). The adopted
peptide substrates (Invitrogen/Biaffin) for kinase phosphorylation
are: AEEEIYGEFEAKKKKG for unphosphorylated Brc-Abl (Schindler
et al., 2000), KVVEEINGNNYVYIDPTQLPY for C-kit (Timokhina et al.,
1998), GLARLIEDNEYTAREGAKFPI for Lck (Perlmutter et al., 1988),
GCSPALKRSHSDSLDHDIFQL for Chk1 (Zhao et al., 2002), and
EGLGPGDTTSTFCGTPNYIAP for Pdk1 (Le Good et al., 1998).
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